These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30471054)

  • 1. Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):287-297. PubMed ID: 30471054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Did Generic Clopidogrel Commercialization Affect Trends of ER Consultations and Hospitalizations in the Population Treated with Clopidogrel?
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Drugs Aging; 2019 Aug; 36(8):759-768. PubMed ID: 31073846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brand name versus generic warfarin: a systematic review of the literature.
    Dentali F; Donadini MP; Clark N; Crowther MA; Garcia D; Hylek E; Witt DM; Ageno W;
    Pharmacotherapy; 2011 Apr; 31(4):386-93. PubMed ID: 21449627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians.
    Pereira JA; Holbrook AM; Dolovich L; Goldsmith C; Thabane L; Douketis JD; Crowther M; Bates SM; Ginsberg JS
    Can J Clin Pharmacol; 2005; 12(3):e229-39. PubMed ID: 16278495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of generic versus brand-name antiepileptic medications.
    Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
    Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risks and costs of multiple-generic substitution of topiramate.
    Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
    Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis.
    Ghate SR; Biskupiak JE; Ye X; Hagan M; Kwong WJ; Fox ES; Brixner DI
    Ann Pharmacother; 2011 Jun; 45(6):701-12. PubMed ID: 21666081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
    Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly JG; Fischer MA; Kesselheim AS; Gagne JJ
    PLoS Med; 2019 Mar; 16(3):e1002763. PubMed ID: 30865626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Beaudoin C; Poirier P
    Drugs R D; 2020 Jun; 20(2):135-145. PubMed ID: 32342284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis.
    Leclerc J; Thibault M; Midiani Gonella J; Beaudoin C; Sampalis J
    Drugs; 2020 May; 80(7):697-710. PubMed ID: 32279239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
    Borgheini G
    Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials.
    Pereira JA; Holbrook AM; Dolovich L; Goldsmith C; Thabane L; Douketis JD; Crowther MA; Bates SM; Ginsberg JS
    Ann Pharmacother; 2005; 39(7-8):1188-93. PubMed ID: 15914517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituting warfarin products: what's the source of the problem?
    Haines ST
    Ann Pharmacother; 2011 Jun; 45(6):807-9. PubMed ID: 21666090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brand-Name Antidepressants Outperform Their Generic Counterparts in Preventing Hospitalization for Depression: The Real-World Evidence from Taiwan.
    Hsu CW; Lee SY; Yang YH; Wang LJ
    Int J Neuropsychopharmacol; 2020 Dec; 23(10):653-661. PubMed ID: 32598470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generics: keep a balanced view.
    Prescrire Int; 2014 Feb; 23(146):52-5. PubMed ID: 24669392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are generic and brand-name statins clinically equivalent? Evidence from a real data-base.
    Corrao G; Soranna D; Arfè A; Casula M; Tragni E; Merlino L; Mancia G; Catapano AL
    Eur J Intern Med; 2014 Oct; 25(8):745-50. PubMed ID: 25200803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating In Vitro, Modeling, and In Vivo Approaches to Investigate Warfarin Bioequivalence.
    Zhang X; Wen H; Fan J; Vince B; Li T; Gao W; Kinjo M; Brown J; Sun W; Jiang W; Lionberger R
    CPT Pharmacometrics Syst Pharmacol; 2017 Aug; 6(8):523-531. PubMed ID: 28379643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
    Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
    Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.